CN107233299A - It is a kind of to be used to treat Loratadine paste of itch and preparation method thereof - Google Patents
It is a kind of to be used to treat Loratadine paste of itch and preparation method thereof Download PDFInfo
- Publication number
- CN107233299A CN107233299A CN201710440771.6A CN201710440771A CN107233299A CN 107233299 A CN107233299 A CN 107233299A CN 201710440771 A CN201710440771 A CN 201710440771A CN 107233299 A CN107233299 A CN 107233299A
- Authority
- CN
- China
- Prior art keywords
- loratadine
- parts
- paste
- itch
- mixed system
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K31/125—Camphor; Nuclear substituted derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to ointment and its preparing technical field, Loratadine paste of itch and preparation method thereof is more particularly, to treated, the Loratadine paste for being used to treat itch is composed of the following components by mass fraction：1~30 part of Loratadine, 1~30 part of fatty acid alkali metal salt, 10~80 parts of monohydric alcohol, 0.5~50 part of polyalcohol, 2~10 parts of auxiliary material, 15~40 parts of auxiliary agent, the auxiliary material are camphor or the extract of peppermint；The Loratadine cream Transdermal absorption that the present invention is provided is fast, small to skin irritatin, few using raw material, cost is low, and preparation technology is simple, can be used for red and swollen and itch caused by treatment bite by mosquitos, the allergic patient for being adapted to different age group uses, can be to be applicable.
Description
Technical field
The present invention relates to ointment and its preparing technical field, more particularly to a kind of Loratadine paste for being used to treat itch
And preparation method thereof.
Background technology
In recent years, due to the change of weather and environment, various pernicious gases, dust and other pollution sources are emerged in multitude,
Becoming causes people to produce various anaphylactoid sensibiligens.The transition in season, field work, pollen hypersensitivity, suction has
Evil gas and grit etc., cause increasing crowd to suffer from various types of anaphylactia, such as allergic rhinitis, nettle
Measles, red swelling of the skin, itch, asthma etc. caused by red point and anaphylactogen are extremely common.Therefore, note environmental change, strengthen
Itself nursing, exploitation treatment anaphylaxis medicine is all very important.Loratadine is an orally active third generation antihistamine
Medicine, the effect with selective depression peripheral H1-receptor, Loratadine is as a kind of potent antiallergic, with advantages below：
1st, potent antihistamine effect is studies have found that Loratadine is rapid-action, long action time, it is oral after 30~60 minutes, allergic symptom
Start to disappear, clinic suppressed peak at 2~4 hours, and its internal liver metabolism thing descarboethoxyloratadine still has very
High activity.2nd, medicining times are less in Clinical practice, and this product need to only be taken once daily, reduce the medicining times of patient,
Improve the compliance of patient.3rd, the small adult of dosage once a day, only need to take this product 10mg every time.4. not with cardiac muscle cell's
Lipid molecular is combined, it is to avoid to the electro physiology process of cardiac muscle cell, therefore without cardiac toxic.
Although the characteristics of Loratadine has above-mentioned excellent, the clinically skin hypersensitivity more obstinate to some now
Disease, dermatitis are still without highly desirable medicine.Environmental pollution caused by increasing chemical substance so that modern industry
The incidence of disease of allergic and dermatitis remains high in society, for these years, and people have been working hard powerful anti-of development efficacy
Allergy and anti-inflammatory drug, to carry out effective control to the allergic and scytitis often occurred in modern industrial society
Treat, after Loratadine absorbs through intestines and stomach, skin is cycled to reach through blood, although certain therapeutic effect, but it can be reached
The adverse reaction such as maincenter calmness limit its heavy dose of application, adult takes this product 40-180mg, can occur obvious
It is drowsiness, the adverse reaction such as arrhythmia cordis and headache.In the case where taking 10mg dosage daily, still have headache, drowsiness, weak, dry,
It is neurotic, pant, overexercise, stomachache, conjunctivitis, stutter, depression, the incidence of numerous adverse reactions such as the infection of the upper respiratory tract
More than 2%.Loratadine can specifically compete peripheral H1-receptor, the effect of blocking histamine with long-acting, strength.But in skin table
Concentration in layer tissue is relatively low.Histamine is the main medium of allergy, and histamine is mainly by mast cell and basocyte
Etc. histidine is disengaged, the latter is changed into histamine through enzyme decarboxylation.The skin wheal and erythema all referred in many skin allergic reactions
In reaction, histamine plays critically important effect, and it has the direct effect to blood vessel, and vasodilator is penetrating with enhancing capilary
Property and cause the neurogenic erythematous response of wide scope.Histamine H 1 receptor antagonist can with histamine competitive effect cell
Histamine H1-receptor, prevents histamine to be combined from same H1 acceptors, so as to suppress its caused allergic reaction.Loratadine is anti-for the third generation
Histamine drug, with more highly polar, not easily passs through blood-brain barrier, thus the obvious drowsiness work without early stage strong lipophilicity antihistamine
With Loratadine is higher than the affinity of maincenter H1 acceptors to the H1 acceptors of peripheral organs cell surface, i.e., have to peripheral H1-receptor
There is high selectivity, advantage is that maincenter sedation is substantially reduced.Because Loratadine is in the relatively small number of skin surface of blood flow
Concentration distribution in tissue is relatively low, and this is very unfavorable for the treatment of allergic skin disease.
The content of the invention
In view of the shortcomings of the prior art, the present invention provides a kind of Loratadine paste for being used to treat itch, and it has saturating
Skin absorbs fast, small to skin irritatin effect.
The present inventor passes through the discovery that studies for a long period of time：For the common oral preparation of Loratadine, mainly pass through
After intestines and stomach absorb, then it is distributed in the dermal tissue of skin by blood circulation, so that the effect of antagonism inflammatory mediator histamine.
Reach the therapeutic action to whole skin allergic inflammation.The blood distribution of skin histology is relatively fewer, and this causes Loratadine
Tissue distribution be unfavorable for very much its treatment to skin allergic disease and dermatitis, oral route heavy dose application is to disease of skin
For there may be the danger of serious systemic adverse reactions, be a kind of very undesirable administering mode.And for clinically
Common allergic and scytitis, its pathogenesis is also very complicated, and is not merely mediated by histamine, thus existing
It is not very good to allergic and scytitis therapeutic effect in clinical treatment medicine.To skin allergic disease
A kind of preferable medicine or pharmaceutical dosage form are found, vast dermatosis patient is badly in need of.
A kind of Loratadine paste for being used to treat itch, it is composed of the following components by mass fraction：Loratadine 1~30
Part, 1~30 part of fatty acid alkali metal salt, 10~80 parts of monohydric alcohol, 0.5~50 part of polyalcohol, 2~10 parts of auxiliary material, auxiliary agent 15~
40 parts；
The auxiliary material is camphor or the extract of peppermint.
It is preferred that, the Loratadine paste for being used to treat itch is composed of the following components by mass fraction：The blood
Full grass anti-inflammatory analgetic hard ointment, by weight, by following material composition：1~30 part of Loratadine, fatty acid alkali metal salt 4
~15 parts, 50~70 parts of monohydric alcohol, 0.5~50 part of polyalcohol, 2~10 parts of auxiliary material, 15~40 parts of auxiliary agent.
It is preferred that, the fatty acid alkali metal salt is capric acid, myristic acid, palmitic acid, stearic acid, oleic acid, 11 carbon
At least one of olefin(e) acid, linoleic acid, alkali metal salt of leukotrienes etc..
It is preferred that, the monohydric alcohol is at least one of monohydric alcohol of carbon atom quantity 6 or less than 6.
It is preferred that, the auxiliary agent is at least one of emulsifying agent, preservative, transdermal enhancer and thickener.
It is preferred that, the emulsifying agent is selected from odium stearate, stearic acid, enuatrol, lauryl sodium sulfate, cetyl sulphur
At least one of sour sodium, sulfated castor oil, single stearic acid glycerine lipoprotein and Tween-80.
It is preferred that, described preservative be selected from benzalkonium bromide, chlorhexidine acetate, sodium benzoate, citric acid, methyl hydroxybenzoate and
One or more in Nipasol；
Described transdermal enhancer is urea；
One or more of the described thickener in lanolin, beeswax, atoleine, albolene and octadecyl alcolol.
It is preferred that, its compressed value is being 300~4000gf/cm2, fusing point is 30~80 DEG C.
It is preferred that, its compressed value is being 500~3000gf/cm2, fusing point is 45-75 DEG C.
A kind of preparation method for being used to treat the Loratadine paste of itch, comprises the following steps：
(1) Loratadine, fatty acid alkali metal salt are dissolved in monohydric alcohol, and removed with 0.2~0.3 μm of membrane filtration
Bacterium, obtains mixed system 1；
(2) auxiliary material and auxiliary agent are well mixed in polyalcohol, and sterilized 30~40 minutes under the conditions of 121~125 DEG C,
Obtain mixed system 2；
(3) mixed system 1 is well mixed with mixed system 2, obtains mixed system 3, gained mixed system 3 is pumped into and cut
Cut in tank；Under normal temperature condition, open cutter low speed 1000~1750r/min and shear 8~10 minutes, then at a high speed 2500~
2880r/min is sheared 4~5 minutes；Cutter is closed, stirring is opened, continues to stir 5~10 in the case where rotating speed is 60~90r/min
Minute, then stirred again in the case where speed of agitator is 30~50r/min, stop stirring when being cooled to 30~35 DEG C, full inspection, packaging,
Produce.
Compared with prior art, the present invention has following technique effect：
Loratadine is prepared into local topical formulation, by Transdermal absorption, increase body allergic inflammation area skin
Local organization free drug concentration, can effective antagonizing histamine sensitization, more preferably play its local antiallergy and anti-inflammatory curative effect,
Reduce adverse reaction.But Loratadine is difficult percutaneous cuticula, it is merely able to rest on the surface of skin, prior art is recognized
Keratoderma can not possibly be passed through for its external application, it is impossible to effective tissue concentration is reached in skin histology, thus can not be played
The curative effect of its antiallergy and anti-inflammatory.
In a word, the Loratadine cream Transdermal absorption that the present invention is provided is fast, small to skin irritatin, few using raw material, into
This is low, and preparation technology is simple, can be used for red and swollen and itch caused by treatment bite by mosquitos.It is adapted to the skin mistake of different age group
Quick patient uses, can be to be applicable.
Embodiment
In order to make the purpose , technical scheme and advantage of the present invention be clearer, with reference to embodiments, to the present invention
It is further elaborated.It should be appreciated that the specific embodiments described herein are merely illustrative of the present invention, it is not used to
Limit the present invention.
Embodiment 1
A kind of Loratadine paste for being used to treat itch, it is characterised in that composed of the following components by mass fraction：Chlorine
It is 15 parts of Lei Tading, 12 parts of capric acid sodium, 60 parts of methanol, 20 parts of 2 one propane diols, 2 parts of Camphora extract, 5 parts of mint extract, hard
5 parts of resin acid sodium, 8 parts of sulfated castor oil, 12 parts of lanolin, 5 parts of albolene；
The invention also discloses the preparation method that this is used to treat the Loratadine paste of itch, comprise the following steps：
(1) Loratadine, capric acid sodium are dissolved in methanol, and it is degerming with 0.2 μm of membrane filtration, obtain mixed system
1；
(2) by Camphora extract, mint extract, odium stearate, sulfated castor oil, lanolin, albolene 2 one
It is well mixed, and is sterilized 35 minutes under the conditions of 123 DEG C in propane diols, obtains mixed system 2；
(3) mixed system 1 is well mixed with mixed system 2, obtains mixed system 3, gained mixed system 3 is pumped into and cut
Cut in tank；Under normal temperature condition, open cutter low speed 1500r/min and shear 10 minutes, then high speed 2600r/min shearings 4
Minute；Cutter is closed, stirring is opened, continues to stir 5 minutes in the case where rotating speed is 70r/min, is then in speed of agitator again
Stirred under 40r/min, stop stirring when being cooled to 30 DEG C, full inspection, packaging is produced.
The compressed value of the Loratadine paste is being 3500gf/cm2, fusing point is 60 DEG C.
Embodiment 2
A kind of Loratadine paste for being used to treat itch, it is characterised in that composed of the following components by mass fraction：Chlorine
15 parts of Lei Tading, 14 parts of capric acid sodium, 60 parts of ethanol, 10 parts of pentaerythrite, 5 parts of mint extract, 5 parts of myristic acid, list are hard
10 parts of resin acid glyceride, 2 parts of chlorhexidine acetate, 3 parts of urea, 10 parts of octadecyl alcolol；
The invention also discloses the preparation method that this is used to treat the Loratadine paste of itch, comprise the following steps：
(1) Loratadine, capric acid sodium are dissolved in ethanol, and it is degerming with 0.25 μm of membrane filtration, obtain mixture
It is 1；
(2) by mint extract, myristic acid, single stearic acid glycerine lipoprotein, chlorhexidine acetate, urea, octadecyl alcolol in season penta
It is well mixed, and is sterilized 35 minutes under the conditions of 124 DEG C in tetrol, obtains mixed system 2；
(3) mixed system 1 is well mixed with mixed system 2, obtains mixed system 3, gained mixed system 3 is pumped into and cut
Cut in tank；Under normal temperature condition, open cutter low speed 1500r/min and shear 10 minutes, then high speed 2600r/min shearings 4
Minute；Cutter is closed, stirring is opened, continues to stir 5 minutes in the case where rotating speed is 70r/min, is then in speed of agitator again
Stirred under 40r/min, stop stirring when being cooled to 30 DEG C, full inspection, packaging is produced.
The compressed value of the Loratadine paste is being 3000gf/cm2, fusing point is 55 DEG C.
Embodiment 3
A kind of Loratadine paste for being used to treat itch, it is characterised in that composed of the following components by mass fraction：Chlorine
1 part of Lei Tading, 4 parts of potassium myristate, 50 parts of n-butanol, 0.5 part of glycerine, 2 parts of Camphora extract, 5 parts of sulfated castor oil,
10 parts of atoleine
The invention also discloses the preparation method that this is used to treat the Loratadine paste of itch, comprise the following steps：
(1) Loratadine, potassium myristate are dissolved in n-butanol, and it is degerming with 0.3 μm of membrane filtration, mixed
System 1；
(2) Camphora extract, sulfated castor oil, atoleine are well mixed in glycerine, and in 121 DEG C of conditions
Lower sterilizing 35 minutes, obtains mixed system 2；
(3) mixed system 1 is well mixed with mixed system 2, obtains mixed system 3, gained mixed system 3 is pumped into and cut
Cut in tank；Under normal temperature condition, open cutter low speed 1200r/min and shear 9 minutes, then 4 points of high speed 2600r/min shearings
Clock；Close cutter, open stirring, rotating speed be 70r/min under continue stir 7 minutes, then again speed of agitator be 40r/
Stirred under min, stop stirring when being cooled to 30 DEG C, full inspection, packaging is produced.
The compressed value of the Loratadine paste is being 2000gf/cm2, fusing point is 30 DEG C；
Embodiment 4
A kind of Loratadine paste for being used to treat itch, it is characterised in that composed of the following components by mass fraction：Chlorine
30 parts of Lei Tading, 15 parts of linoleic acid sodium, 70 parts of ethanol, 50 parts of ethylene glycol, 5 parts of Camphora extract, 5 parts of mint extract, tristearin
Sour 5 parts of sodium, 3 parts of stearic acid, 2 parts of benzalkonium bromide, 3 parts of urea, 12 parts of lanolin, 15 parts of beeswax；
The invention also discloses the preparation method that this is used to treat the Loratadine paste of itch, comprise the following steps：
(1) Loratadine, linoleic acid sodium are dissolved in ethanol, and it is degerming with 0.2 μm of membrane filtration, obtain mixed system
1；
(2) by Camphora extract, mint extract, odium stearate, stearic acid, benzalkonium bromide, urea, lanolin, beeswax
It is well mixed, and is sterilized 30 minutes under the conditions of 123 DEG C in ethylene glycol, obtains mixed system 2；
(3) mixed system 1 is well mixed with mixed system 2, obtains mixed system 3, gained mixed system 3 is pumped into and cut
Cut in tank；Under normal temperature condition, open cutter low speed 1300r/min and shear 9 minutes, then 5 points of high speed 2600r/min shearings
Clock；Close cutter, open stirring, rotating speed be 70r/min under continue stir 8 minutes, then again speed of agitator be 36r/
Stirred under min, stop stirring when being cooled to 32 DEG C, full inspection, packaging is produced.
The compressed value of the Loratadine paste is being 500gf/cm2, fusing point is 60 DEG C.
Embodiment 5
A kind of Loratadine paste for being used to treat itch, it is characterised in that composed of the following components by mass fraction：Chlorine
1 part of Lei Tading, 4 parts of Sodium myristate, 50 parts of n-butanol, 50 parts of trimethylolethane, 5 parts of Camphora extract, mint extract 5
Part, 5 parts of odium stearate, 3 parts of stearic acid, 3 parts of urea, 12 parts of lanolin, 15 parts of beeswax；
The invention also discloses the preparation method that this is used to treat the Loratadine paste of itch, comprise the following steps：
(1) Loratadine, Sodium myristate are dissolved in n-butanol, and it is degerming with 0.2 μm of membrane filtration, mixed
System 1；
(2) by Camphora extract, mint extract, odium stearate, stearic acid, urea, lanolin, beeswax in trihydroxy methyl
It is well mixed, and is sterilized 30 minutes under the conditions of 123 DEG C in ethane, obtains mixed system 2；
(3) mixed system 1 is well mixed with mixed system 2, obtains mixed system 3, gained mixed system 3 is pumped into and cut
Cut in tank；Under normal temperature condition, open cutter low speed 1300r/min and shear 9 minutes, then 5 points of high speed 2600r/min shearings
Clock；Close cutter, open stirring, rotating speed be 70r/min under continue stir 8 minutes, then again speed of agitator be 36r/
Stirred under min, stop stirring when being cooled to 32 DEG C, full inspection, packaging is produced.
The compressed value of the Loratadine paste is being 385gf/cm2, fusing point is 68 DEG C；
Foregoing description is only the description to section Example of the present invention, not to any restriction of the scope of the invention, one's own profession
The those of ordinary skill of industry can make improvement according to the present invention or change to above-described embodiment, but belong to present invention protection model
Enclose.
Claims (9)
1. a kind of Loratadine paste for being used to treat itch, it is characterised in that composed of the following components by mass fraction：Chlorine thunder
He fixed 1~30 part, 1~30 part of fatty acid alkali metal salt, 10~80 parts of monohydric alcohol, 0.5~50 part of polyalcohol, 2~10 parts of auxiliary material,
15~40 parts of auxiliary agent；
The auxiliary material is camphor or the extract of peppermint.
2. the Loratadine paste as claimed in claim 1 for being used to treat itch, it is characterised in that by mass fraction by following
Component is constituted：1~30 part of Loratadine, 4~15 parts of fatty acid alkali metal salt, 50~70 parts of monohydric alcohol, polyalcohol 0.5~50
Part, 2~10 parts of auxiliary material, 15~40 parts of auxiliary agent.
3. the Loratadine paste as claimed in claim 2 for being used to treat itch, it is characterised in that the fatty acid alkali metal
Salt is capric acid, myristic acid, palmitic acid, stearic acid, oleic acid, undecenoic acid, linoleic acid, in the alkali metal salt of leukotrienes etc.
At least one.
4. the Loratadine paste as claimed in claim 3 for being used to treat itch, it is characterised in that the monohydric alcohol is carbon containing
At least one of monohydric alcohol that atomicity is 6 or less than 6.
5. the Loratadine paste as claimed in claim 4 for being used to treat itch, it is characterised in that the auxiliary agent is emulsification
At least one of agent, preservative, transdermal enhancer and thickener.
6. the Loratadine paste as claimed in claim 5 for being used to treat itch, it is characterised in that the emulsifying agent is selected from hard
Resin acid sodium, stearic acid, enuatrol, lauryl sodium sulfate, sodium hexadecyl sulfate, sulfated castor oil, glycerol monostearate
At least one of fat and Tween-80.
7. the Loratadine paste as claimed in claim 6 for being used to treat itch, it is characterised in that its compressed value is being 300
~4000gf/cm2, fusing point is 30~80 DEG C.
8. the Loratadine paste as claimed in claim 7 for being used to treat itch, it is characterised in that its compressed value is being 500
~3000gf/cm2, fusing point is 45-75 DEG C.
9. being used for as described in claim 1~8 is any treats the preparation method of the Loratadine paste of itch, its feature exists
In comprising the following steps：
(1) Loratadine, fatty acid alkali metal salt are dissolved in monohydric alcohol, and it is degerming with 0.2~0.3 μm of membrane filtration, obtain
To mixed system 1；
(2) auxiliary material and auxiliary agent are well mixed in polyalcohol, and sterilized 30~40 minutes under the conditions of 121~125 DEG C, obtained
Mixed system 2；
(3) mixed system 1 is well mixed with mixed system 2, obtains mixed system 3, gained mixed system 3 is pumped into shearing tank
In；Under normal temperature condition, open cutter low speed 1000~1750r/min and shear 8~10 minutes, then at a high speed 2500~
2880r/min is sheared 4~5 minutes；Cutter is closed, stirring is opened, continues to stir 5~10 in the case where rotating speed is 60~90r/min
Minute, then stirred again in the case where speed of agitator is 30~50r/min, stop stirring when being cooled to 30~35 DEG C, full inspection, packaging,
Produce.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710440771.6A CN107233299A (en) | 2017-06-13 | 2017-06-13 | It is a kind of to be used to treat Loratadine paste of itch and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710440771.6A CN107233299A (en) | 2017-06-13 | 2017-06-13 | It is a kind of to be used to treat Loratadine paste of itch and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107233299A true CN107233299A (en) | 2017-10-10 |
Family
ID=59987383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710440771.6A Pending CN107233299A (en) | 2017-06-13 | 2017-06-13 | It is a kind of to be used to treat Loratadine paste of itch and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107233299A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101991574A (en) * | 2009-08-27 | 2011-03-30 | 杭州赛利药物研究所有限公司 | Desloratadine external preparation and preparation method thereof |
| CN102048682A (en) * | 2009-10-31 | 2011-05-11 | 鲁南制药集团股份有限公司 | Loratadine cream and application thereof |
| WO2012015789A2 (en) * | 2010-07-27 | 2012-02-02 | Sara Beth Ford | Composition and method for the topicaltreatment of dermatitis |
| CN102764230A (en) * | 2011-05-06 | 2012-11-07 | 上海现代制药股份有限公司 | Nasal gel or ointment preparation for preventing and/or treating aspiration allergy |
| CN103877086A (en) * | 2012-12-20 | 2014-06-25 | 杭州赛利药物研究所有限公司 | New application of desloratadine in pharmacy |
| CN105943586A (en) * | 2016-06-15 | 2016-09-21 | 云南中医学院 | Sambucus adnata hard ointment capable of diminishing inflammation and relieving pain and preparation method thereof |
-
2017
- 2017-06-13 CN CN201710440771.6A patent/CN107233299A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101991574A (en) * | 2009-08-27 | 2011-03-30 | 杭州赛利药物研究所有限公司 | Desloratadine external preparation and preparation method thereof |
| CN102048682A (en) * | 2009-10-31 | 2011-05-11 | 鲁南制药集团股份有限公司 | Loratadine cream and application thereof |
| WO2012015789A2 (en) * | 2010-07-27 | 2012-02-02 | Sara Beth Ford | Composition and method for the topicaltreatment of dermatitis |
| CN102764230A (en) * | 2011-05-06 | 2012-11-07 | 上海现代制药股份有限公司 | Nasal gel or ointment preparation for preventing and/or treating aspiration allergy |
| CN103877086A (en) * | 2012-12-20 | 2014-06-25 | 杭州赛利药物研究所有限公司 | New application of desloratadine in pharmacy |
| CN105943586A (en) * | 2016-06-15 | 2016-09-21 | 云南中医学院 | Sambucus adnata hard ointment capable of diminishing inflammation and relieving pain and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210100759A1 (en) | Pain relief compositions, manufacture and uses | |
| EP3131531B1 (en) | Topical compositions for pain relief, manufacture and use | |
| US20210353594A1 (en) | Apremilast pharmaceutical compositions and methods | |
| CN109481386A (en) | A kind of infant's multiple-effect nursing creams and preparation method thereof | |
| JP6666068B2 (en) | External composition | |
| US20170290804A1 (en) | Treatment of atopic dermatitis with indigo naturalis or indigo producing plant extract | |
| EP2705847B1 (en) | Composition for treating psoriasis | |
| US20130274321A1 (en) | Topical Compositions with Cannabis Extracts | |
| CN111050767A (en) | Composition for preventing or treating sleep disorders | |
| WO2021030190A1 (en) | Cbd formulations and uses thereof | |
| US20120225143A1 (en) | Cold sore formulation and related method of manufacture | |
| WO2024041083A1 (en) | Antifungal solution, preparation method therefor, and use thereof | |
| CN107233299A (en) | It is a kind of to be used to treat Loratadine paste of itch and preparation method thereof | |
| JP7313111B2 (en) | Sebum secretion stimulator and composition for external use | |
| JP7361448B2 (en) | Transglutaminase expression promoter | |
| JP4499425B2 (en) | Transdermal absorption enhancer and athlete's foot treatment composition | |
| US12059393B2 (en) | Compositions for topical treatment of radiation dermatitis | |
| JP4101464B2 (en) | Anti-inflammatory ointment | |
| Nankervis et al. | Emollients and other topical treatments | |
| EP4362935A1 (en) | Methods for treatment of opioid use disorder with cannabinoids | |
| WO2024159051A1 (en) | Treatment of chronic pruritic dermatoses | |
| CN102451180A (en) | External medicine for treating skin diseases and preparation method thereof | |
| WO2003080096A1 (en) | Compositions for treating and/or preventing pollenosis | |
| CN106924178A (en) | A kind of Oxiconazole Nitrate nanometer emulsifiable paste and preparation method thereof | |
| KR20050114061A (en) | Pharmaceutical composition consisting of l-2-oxothiazolidine-4-carboxylic acid or its salts for psoriasis therapeutic agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171010 |